What is Spyre Therapeutics Inc.?
, a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 9.88B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 0 | 0 |
| 6-9months | 547,958 shares $2.2M | 0 |
| 9-12months | 345,000 shares $1.4M | 0 |